Telo Genomics Corp. announced that the Company has signed a collaboration agreement with Emery Pharma. Emery is a full-service contract research organization (CRO) offering biologic drug development support and analytical characterization, and this agreement will facilitate its collaboration with Telo in providing a more comprehensive service.

Telo and Emery have unique innovative technologies and expertise, presenting a significant opportunity to offer complimentary cellular and molecular bioanalytical solutions for clinical research and development initiatives to their respective clients. The executed MOU provides a framework to develop collaborations and validate the complimentary utility of both platforms, and offer value added information to address complex pharma and diagnostics unmet needs. Telo Genomics capitalizes on telomere features as 3-dimensional structural biomarkers quantified by its proprietary TeloView platform to inform on the level of genomic instability with high sensitivity, offering value added information for oncology and genetic diseases.

The TeloView technology is conducted on the level of the single cell and applicable to liquid biopsy, which positions the technology at the forefront of precision medicine. Emery Pharma specializes in the characterization of biologics with an extensive array of services, ranging from intact mass analysis, peptide mapping, and glycan analysis, to host cell proteins, post-translational modifications, immunogenicity analysis, and general R&D and cGMP/GLP support. Emery Pharma's unique approach delivers high-quality actionable data for drug development programs.